CCL2 and COVID-19: It was reported that CD147 contributes to T cell metabolic dysfunction and dysregulation of inflammation in patients with COVID-19.29 We have proved that meplazumab could effectively block the SARS-CoV-2-induced cytokine release.11 In this study, several cytokine storm-related cytokines, including the IL-4, IL-8, MCP-1, and IFN-γ levels were significantly reduced by meplazumab.